RSS

pain and inflammation drugs

Novartis International will acquire Spinifex Pharmaceuticals, a developer of drugs for chronic pain, for an upfront cash consideration of $200 million, plus undisclosed clinical development and regulatory milestone payments. more

News

AYOXXA Biosystems and Grünenthal have been using AYOXXA's protein multiplexing technology platform to analyse an inflammation marker at very low concentrations released from human cells following treatment in cell culture experiments. more

News